Biotechnology Companies By Roa

Return On Asset
ROAEfficiencyMarket RiskExp Return
1PTGX Protagonist Therapeutics
0.29
 0.09 
 6.47 
 0.58 
2ADMA ADMA Biologics
0.21
 0.08 
 3.35 
 0.26 
3CPRX Catalyst Pharmaceuticals
0.18
 0.06 
 3.18 
 0.19 
4HALO Halozyme Therapeutics
0.18
 0.38 
 1.40 
 0.54 
5IRWD Ironwood Pharmaceuticals
0.15
(0.24)
 6.30 
(1.52)
6MDXG MiMedx Group
0.15
(0.11)
 1.81 
(0.20)
7EXEL Exelixis
0.15
 0.09 
 2.41 
 0.21 
8KPRX Kiora Pharmaceuticals
0.13
 0.01 
 3.97 
 0.03 
9VRTX Vertex Pharmaceuticals
0.13
 0.29 
 1.48 
 0.43 
10ALKS Alkermes Plc
0.13
 0.13 
 1.89 
 0.24 
11UTHR United Therapeutics
0.12
(0.09)
 2.30 
(0.20)
12ESPR Esperion Therapeutics
0.12
(0.12)
 3.59 
(0.44)
13GILD Gilead Sciences
0.11
 0.16 
 1.59 
 0.25 
14GMAB Genmab AS
0.11
 0.00 
 2.79 
 0.00 
15RIGL Rigel Pharmaceuticals
0.11
 0.09 
 4.45 
 0.39 
16INDV Indivior PLC Ordinary
0.11
(0.06)
 3.91 
(0.23)
17NBIX Neurocrine Biosciences
0.1
(0.11)
 2.81 
(0.30)
18CTMX CytomX Therapeutics
0.0969
(0.15)
 4.70 
(0.71)
19MNKD MannKind Corp
0.0912
(0.21)
 2.03 
(0.42)
20PBYI Puma Biotechnology
0.0872
 0.10 
 4.89 
 0.47 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time. Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.